New Advances in Thrombosis and Hemostasis

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Hematology".

Deadline for manuscript submissions: 25 May 2024 | Viewed by 920

Special Issue Editor


E-Mail Website
Guest Editor
1. Katharine Dormandy Haemophilia and Thrombosis Centre, Royal Free Hospital, London NW3 2QG, UK
2. Research Department of Haematology, University College London, London WC1E 6BT, UK
Interests: haemostasis and haemophilia; haematology; thrombosis; inherited and acquired bleeding and thrombotic disorders
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Hemostasis and thrombosis have seen some phenomenal changes in both diagnosis and management. Several innovations have resulted in paradigm shifts in the management of life-threatening disorders. We are entering an era of increased choice and associated challenges, where the focus on is the optimization of care and equity of access.  

This Special Issue is devoted to the state of the art and areas that have not been the subject of intense focus to date in the fields of hemostasis, thrombosis, and angiology. We look forward to your contributions.

Prof. Dr. Pratima Chowdary
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • thrombosis
  • hemostasis
  • platelet
  • vascular
  • angiology
  • coagulation
  • venous and arterial
  • bleeding
  • anti-platelet drugs
  • anti-thrombotic drugs
  • hemophilia
  • cardiovascular disease
  • hematology

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Other

10 pages, 4277 KiB  
Project Report
Antiphospholipid Antibody Testing: An Audit on Testing Practices in a Public Tertiary Care Center
by Eman M. Mansory, Hatem M. Alahwal, Salem M. Bahashwan, Osman Radhwi, Abdullah T. Almohammadi, Yassir Daghistani, Jamil Al-Mughales and Ahmed S. Barefah
J. Clin. Med. 2024, 13(1), 243; https://doi.org/10.3390/jcm13010243 - 31 Dec 2023
Viewed by 726
Abstract
Background: Antiphospholipid antibodies (aPLs) are antibodies directed against cell membrane components and can be associated with clinical features or be asymptomatic. Testing and interpreting these antibodies is associated with many challenges and pitfalls in clinical practice. Objective: To review all antiphospholipid antibody testing [...] Read more.
Background: Antiphospholipid antibodies (aPLs) are antibodies directed against cell membrane components and can be associated with clinical features or be asymptomatic. Testing and interpreting these antibodies is associated with many challenges and pitfalls in clinical practice. Objective: To review all antiphospholipid antibody testing and describe the testing practices, indications for testing and interpretation of results to infer local challenges with aPL testing and subsequently address ways to overcome those challenges. Methods: This is a retrospective analysis of all aPL testing done in a tertiary center between 2014 and 2018. Characteristics of study patients collected through chart review were described using the mean and standard deviation for continuous variables and proportion for categorical variables. Group differences were compared between patients with any aPL-positive result and those with no positive result using chi-square or Fisher’s exact test as appropriate for categorical variables and a simple regression model for numerical variables. Results: Among 414 patients undergoing aPL testing, mainly adult females, 62 (14.9%) patients had at least one positive antibody, of those, 26 (42%) had repeat testing done. Testing was mostly done for obstetric indication (107, 25.8%), with 36 patients having one or two early pregnancy losses <10 weeks as their testing indication. A total of 27 (6.5%) patients were labeled with APS/possible APS based on chart review, but on review of the testing of those patients according to classification criteria, only nine patients satisfied the criteria for APS. Conclusion: This study highlights the clinical challenges associated with aPL testing, including the controversies around indication for testing, the low rates of repeat testing to confirm persistence, and the common misinterpretation of results. Having an aPL testing profile, explicit reference ranges, results commentary, and close interaction between ordering physicians and laboratory staff might be starting points to overcome these challenges. Full article
(This article belongs to the Special Issue New Advances in Thrombosis and Hemostasis)
Show Figures

Figure 1

Back to TopTop